Lead programme.
One disease, taken to its root. A published disease model, a proprietary approach, and a defined next gate.
Why Crohn's disease
Ileal Crohn's has a concentrated genetic architecture, making a gene-level approach computationally tractable in a way that the full polygenic landscape isn't.
We already have a published disease model, a proprietary intervention strategy, and a computational pipeline built specifically for this disease. This is existing work, not a starting point.
The next gate is a single-cell validation study with prespecified pass/fail criteria. Wet-lab validation is funding-dependent.
Ileal Crohn's Disease
Computational validation complete. Seeking funding to cross the single-cell validation gate.
| Code | Indication | Organ | Modality | Stage | Addressable |
|---|---|---|---|---|---|
| VD-101 | Ileal Crohn's disease | Ileum | Gene-level correction | Validation | ~3.6M |
| VD-201 | Undisclosed monogenic indication | — | Gene-level correction | Discovery | — |
| VD-301 | Undisclosed monogenic indication | — | Gene-level correction | Discovery | — |
Programme codes assigned on entry to the scoring pipeline. Disclosure staged as each candidate clears its prespecified gate.
Request Full Programme Details
Detailed programme data is shared under NDA with qualified partners only. The briefing covers:
Available to investors and academic or industry partners under NDA.
→ Request programme details